NASDAQ$SRRK
Scholar Rock Holding Corporation · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Reported financial results for the second quarter ended June 30, 2020.
Scholar Rock reported a net loss of $19.3 million, or $0.65 per share, for the quarter ended June 30, 2020. Revenue for the quarter was $3.9 million, related to the Gilead collaboration. The company's cash, cash equivalents, and marketable securities totaled $141.2 million as of June 30, 2020.
- On track to report interim efficacy and safety results from TOPAZ Phase 2 clinical trial of SRK-015 in patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA) in 4Q20.
- Enrollment expected to advance to combination treatment of SRK-181 and an approved anti-PD-(L)1 therapy in Part A of DRAGON Phase 1 clinical trial in 3Q20; update on dose escalation expected in 4Q20.
- Tony Kingsley appointed as President and CEO and Ted Myles as CFO and Head of Business Operations.
- Company hosting conference call at 8am ET to discuss financial results and introduce newest members of management
Headline financials
Revenue & EPS history
Scholar Rock · Revenue · Quarterly
$3.9M
Forward guidance
Scholar Rock is on track to report interim efficacy and safety data in the fourth quarter of 2020 for SRK-015. Enrollment is expected to advance in the DRAGON Phase 1 trial for SRK-181 in the third quarter of 2020, with an update on dose escalation expected in the fourth quarter of 2020.
Tailwinds
- On track to report interim efficacy and safety results from TOPAZ Phase 2 clinical trial of SRK-015 in patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA) in 4Q20
- Enrollment expected to advance to combination treatment of SRK-181 and an approved anti-PD-(L)1 therapy in Part A of DRAGON Phase 1 clinical trial in 3Q20; update on dose escalation expected in 4Q20
- High level of engagement of trial investigators and patients
- High rate of enrollment into the 12-month extension study for SRK-015 TOPAZ trial
- Pleased with the progress to date enrolling patients in our SRK-181 DRAGON trial
Headwinds
- Three patients missed three doses of SRK-015 due to COVID-19-related restrictions at their trial site, and their 6-month assessments will be excluded from the interim analysis.
- One patient discontinued from the trial for reasons unrelated to the study drug and which occurred prior to the COVID-19 pandemic.
- There may be further impacts on the timing of future doses and assessments for patients in the trial as the effects of the COVID-19 pandemic continue to evolve.
- Net loss of $19.3 million or $0.65 per share compared to a net loss of $12.5 million or $0.48 per share for the quarter ended June 30, 2019.
- Decrease in cash, cash equivalents, and marketable securities from $157.4 million as of December 31, 2019 to $141.2 million as of June 30, 2020.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2020
+3.6%
Avg return
Earnings day
+3.0%
Avg return
5 days after
+3.5%
Avg return
30 days after
58%
18 / 31 earnings
Positive
+24.6%
Q4 2023
Best reaction
-7.6%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.4% | +4.4% | -6.1% | |
| Q4 2025 | +2.0% | +4.2% | +15.0% | |
| Q3 2025 | +24.1% | +32.0% | +55.9% | |
| Q2 2025 | -6.1% | -14.9% | -15.1% | |
| Q1 2025 | -2.6% | -3.9% | +3.3% | |
| Q4 2024 | -2.9% | +0.2% | -11.3% | |
| Q3 2024 | -2.7% | -5.9% | +48.0% | |
| Q1 2024 | -3.7% | -11.4% | -37.4% | |
| Q4 2023 | +24.6% | +24.2% | +5.7% | |
| Q3 2023 | -1.8% | -17.5% | +44.2% | |
| Q2 2023 | +6.3% | +11.6% | -3.6% | |
| Q1 2023 | +4.4% | -0.1% | -13.6% | |
| Q4 2022 | +7.2% | -1.9% | -15.7% | |
| Q3 2022 | +10.9% | +0.2% | +1.5% | |
| Q2 2022 | +6.9% | +32.9% | +5.2% | |
| Q1 2022 | +7.3% | -5.2% | -9.7% | |
| Q4 2021 | -5.1% | -9.5% | -8.6% | |
| Q3 2021 | +16.8% | +24.2% | -10.4% | |
| Q2 2021 | +4.8% | +7.5% | +4.6% | |
| Q1 2021 | -2.4% | +0.1% | +10.6% | |
| Q4 2020 | +16.8% | +21.4% | -40.2% | |
| Q3 2020 | -1.0% | +2.8% | +7.7% | |
| Q2 2020 | +3.9% | -4.1% | +5.0% | |
| Q1 2020 | -4.8% | +6.9% | +2.2% | |
| Q4 2019 | +4.3% | +9.4% | -1.1% | |
| Q3 2019 | -7.6% | -14.5% | +17.0% | |
| Q2 2019 | +0.8% | +11.9% | +19.4% | |
| Q1 2019 | +6.2% | +8.6% | -4.9% | |
| Q4 2018 | +9.8% | +2.3% | -7.4% | |
| Q3 2018 | +2.0% | -10.0% | -1.6% | |
| Q2 2018 | -6.7% | -11.9% | +51.0% | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro